**Supplemental digital content**

**Community-based service delivery of HIV treatment in Zambia: costs and outcomes**

*Nichols BE, Cele R, Jamieson L, Long LC, Siwale Z, Banda P, Moyo C, Rosen S*

**SDC 1.** **DSD interaction estimates scenario descriptions**

|  |  |  |
| --- | --- | --- |
| **Scenario** | **Description** | **Example** |
| Scenario 1: Full DSD use | All patients completed all scheduled DSD interactions and were dispensed ART according to their specific DSD schedule, regardless of the proportion of expected facility-based clinical visits attended. | If a patient attended 50% of her clinical visits, we assume that she still made 100% of her scheduled DSD interactions. If the patient became lost-to-follow-up and no additional facility-based clinical visits were recorded, then DSD interactions were assumed to have stopped as well. |
| Scenario 2: Proportional DSD use | The number of DSD interactions made was proportional to the number of facility-based clinical visits made. | If a patient attended 25% of her expected facility-based clinic visits, we assumed that she also attended 25% of her DSD interactions. |

**SDC 2. Unit costs**

The unit costs assumed for all laboratory tests and medicines are listed in **Tables S1 and S2** below. The laboratory unit costs were derived from the Centre for Infectious Disease Research in Zambia (CIDRZ) 2018 pricelist for laboratory tests. The laboratory costs from the CIDRZ list are private-sector prices. In order to estimate the public-sector prices (for which no price list is available), we looked at the ratio of the cost of a viral load, to the cost of the viral load on the pricelist. We then made an adjustment by the same percentage to all prices on the list (approximately a 50% reduction). These unit costs were then compared to the public sector laboratory costs in South Africa (SA), for which there is a price list, and were found to be roughly the same.

|  |  |
| --- | --- |
| **SDC 3. Laboratory unit costs** | |
| **Laboratory testing item** | **Unit Cost**  **(2018 USD)** |
| CD4 count | 3.66 |
| Viral Load | 17.22 |
| Creatinine | 1.83 |
| FBC | 4.97 |
| ALT/AST | 2.04 |
| Sputum | 2.35 |
| Pregnancy | 5.23 |
| RPR | 1.94 |
| HBsAg | 5.23 |
| Random blood sugar | 1.83 |

**SDC 4.** **Complete list of drug names, doses and unit cost used for analysis**

| **Drug Display Name** | **Dosage** | **Cost (2018 USD)** | **Qty** | **Units** | **Unit Cost (2018 USD)** | **Unit Cost unit** | **Comment** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 3TC+AZT | 150 mg + 300 mg | 6.54 | 60 | tablets | 0.109 | per tablet | MSL catalogue 2016 |
| 3TC+AZT | 30 mg + 60 mg | 3.50 | 60 | tablets | 0.0583333 | per tablet | MSL catalogue 2016 |
| 3TC+D4T | 150 mg + 30 mg | 3.15 | 60 | tablets | 0.0525 | per tablet | MSL catalogue 2016 |
| 3TC+D4T | 150 mg + 40 mg | 3.15 | 60 | tablets | 0.0525 | per tablet | Estimated (30mg price) |
| 3TC+NVP | 150 mg + 200 mg | 4.45 | 60 | tablets | 0.0741667 | per tablet | Estimated (adding 3TC+NVP) |
| 3TC+NVP+AZT | 150 mg + 200 mg + 300 mg | 10.05 | 60 | tablets | 0.1675 | per tablet | Estimated (adding 3TC+NVP+AZT) |
| 3TC+NVP+D4T | 150 mg + 200 mg + 30 mg | 5.35 | 60 | tablets | 0.0891667 | per tablet | Estimated (adding 3TC/D4T+NVP) |
| 3TC+NVP+D4T | 150 mg + 200 mg + 40 mg | 5.35 | 60 | tablets | 0.0891667 | per tablet | Estimated (adding 3TC/D4T+NVP), assuming 30mg |
| 3TC+NVP+D4T | 30 mg + 50 mg + 6 mg |  |  |  | 0.0178333 | per tablet | Estimated relative to 150/200/30mg |
| 3TC+NVP+D4T | 60 mg + 100 mg + 12 mg |  |  |  | 0.0356667 | per tablet | Estimated relative to 30/50/12mg |
| 3TC+TDF | 300 mg + 300 mg | 4.62 | 30 | tablets | 0.154 | per tablet | MSL catalogue 2016 |
| 3TC+TDF | 600 mg + 300 mg + 300 mg | 8.99 | 30 | tablets | 0.2996667 | per tablet | MSL catalogue 2016 |
| ABC+3TC | 60 mg + 30 mg | 3.5 | 30 | tablets | 0.1166667 | per tablet | MSL catalogue 2016 |
| ABC+3TC | 600 mg + 300 mg | 35 | 30 | tablets | 1.1666667 | per tablet | Estimated |
| ABC+3TC+AZT | 300 mg + 150 mg + 300 mg |  |  |  | 0.3258333 | per tablet | Estimated (drugs added individually) |
| EFV+3TC+TDF | 600 mg | 8.99 | 30 | tablets | 0.2996667 | per tablet | MSL catalogue 2016 |
| EFV+FTC+TDF | 600 mg + 200 mg + 300 mg |  |  |  | 0.3254834 | per tablet | Estimated (drugs added individually) |
| FTC+TDF | 200 mg + 300 mg |  |  |  | 0.2188167 | per tablet | Estimated (SA pricing assumptions, relative to TDF) |
| abacavir (ABC) | 20 mg/mL |  |  |  | 0.0272419 | per ml | Estimated (SA pricing assumptions, relative to 60mg) |
| abacavir (ABC) | 300 mg | 11.7 | 60 | tablets | 0.195 | per tablet | MSL catalogue 2016 |
| abacavir (ABC) | 60 mg |  |  |  | 0.0980339 | per tablet | Estimated (SA pricing assumptions, relative to 300mg) |
| acetylsalicylic acid | 300 mg | 3.56 | 1000 | tablets | 0.00356 | per tablet | MSL catalogue 2016 |
| acyclovir | 200 mg | 0.72 | 100 | tablets | 0.0072 | per tablet | MSL catalogue 2016 |
| acyclovir | 400 mg | 1.58 | 100 | tablets | 0.0158 | per tablet | MSL catalogue 2016 |
| acyclovir | 800 mg | 3.16 | 100 | tablets | 0.0316 | per tablet | Estimated (400mgx2) |
| albuterol | 2 mg | 11.30 | 1000 | tablets | 0.0113 | per tablet | MSL catalogue 2016 (as Salbutamol) |
| amiloride+hydrochlorothiazide | 5 mg + 50 mg | 3.03 | 1000 | tablets | 0.00303 | per tablet | MSL catalogue 2016 |
| aminophylline | 100 mg | 14.50 | 1000 | tablets | 0.0145 | per tablet | MSL catalogue 2016 |
| amoxicillin | 200 mg | 5.82 | 1000 | tablets | 0.00582 | per tablet | Using 250mg price |
| amoxicillin | 250 mg | 5.82 | 1000 | tablets | 0.00582 | per tablet | MSL catalogue 2016 |
| amoxicillin | 500 mg | 11.64 | 1000 | tablets | 0.01164 | per tablet | MSL catalogue 2016 |
| aspirin | 300 mg | 3.56 | 1000 | tablets | 0.00356 | per tablet | MSL catalogue 2016 |
| atazanavir | 100 mg |  |  |  | 0.15 | per tablet | Estimated relative to 300mg |
| atazanavir | 300 mg |  |  |  | 0.44 | per tablet | Estimated (ATV/RTV minus RTV) |
| atazanavir+ritanovir | 300 mg | 16.50 | 30 | tablets | 0.55 | per tablet | MSL catalogue 2016 |
| benzathine penicillin | 2000000 units | 0.17 | 1 | injection | 0.17 | per injection | MSL catalogue 2016 |
| cephalexin | 250 mg | 18.30 | 1000 | tablets | 0.0183 | per tablet | MSL catalogue 2016 |
| chlorpheniramine | 2 mg | 4.25 | 1000 | tablets | 0.00425 | per tablet | Estimated half 4mg |
| chlorpheniramine | 4 mg | 8.50 | 1000 | tablets | 0.0085 | per tablet | MSL catalogue 2016 |
| ciprofloxacin | 250 mg | 14.40 | 100 | tablets | 0.144 | per tablet | MSL catalogue 2016 |
| clotrimazole | 10 mg/mL | 0.40 | 1 | tube | 0.4 | per tube | MSL catalogue 2016 |
| cloxacillin | 250 mg | 10.98 | 1000 | tablets | 0.01098 | per tablet | MSL catalogue 2016 |
| diaphenylsulfone | 10 mg |  |  |  | 0.01 | per tablet | Estimated (relative to 100mg) |
| diaphenylsulfone | 100 mg |  |  |  | 0.09 | per tablet | Estimated (relative to RIF, as often given with it) |
| diaphenylsulfone | 25 mg |  |  |  | 0.02 | per tablet | Estimated (100mg/4) |
| diaphenylsulfone | 50 mg |  |  |  | 0.04 | per tablet | Estimated (100mg/2) |
| didanosine (ddI) | 100 mg |  |  |  | 0.2425036 | per tablet | Estimated; relative incr. based on SA data |
| didanosine (ddI) | 150 mg |  |  |  | 0.4379903 | per tablet | Estimated (100mg+50mg) |
| didanosine (ddI) | 25 mg |  |  |  | 0.1510499 | per tablet | Estimated; relative incr. based on SA data |
| didanosine (ddI) | 250 mg |  |  |  | 0.4857294 | per tablet | Estimated; relative incr. based on SA data |
| didanosine (ddI) | 400 mg |  |  |  | 0.7636424 | per tablet | Estimated; relative incr. based on SA data |
| didanosine (ddI) | 50 mg |  |  |  | 0.1954868 | per tablet | Estimated; relative incr. based on SA data |
| doxycycline | 100 mg | 14.43 | 100 | tablets | 0.1443 | per tablet | MSL catalogue 2016 |
| efavirenz (EFV) | 100 mg |  |  |  | 0.0516667 | per tablet | Estimated (200mg/2) |
| efavirenz (EFV) | 200 mg | 9.30 | 90 | tablets | 0.1033333 | per tablet | MSL catalogue 2016 |
| efavirenz (EFV) | 50 mg |  |  |  | 0.1751646 | per tablet | Estimated (200mg/4) |
| efavirenz (EFV) | 600 mg | 3.20 | 30 | tablets | 0.1066667 | per tablet | MSL catalogue 2016 |
| erythromycin | 250 mg | 5.99 | 1000 | tablets | 0.00599 | per tablet | MSL catalogue 2016 |
| ethambutol+isoniazid | 400 mg + 150 mg | 6.21 | 100 | tablets | 0.0621 | per tablet | Estimated as 400mg Eth + 100mg INH |
| ferrous sulfate | 200 mg | 0.63 | 1000 | tablets | 0.00063 | per tablet | MSL catalogue 2016 |
| ferrous sulfate | 50 mg | 0.16 | 1000 | tablets | 0.0001575 | per tablet | Estimated |
| fluconazole | 200 mg | 6.00 | 100 | tablets | 0.06 | per tablet | MSL catalogue 2016 |
| folic acid (vitamin B9) | 5 mg | 0.27 | 1000 | tablets | 0.00027 | per tablet | MSL catalogue 2016 |
| furosemide | 40 mg | 3.01 | 1000 | tablets | 0.00301 | per tablet | MSL catalogue 2016 |
| ibuprofen | 200 mg | 5.9 | 1000 | tablets | 0.0059 | per tablet | MSL catalogue 2016 |
| isoniazid | 100 mg | 3.2 | 100 | tablets | 0.032 | per tablet | MSL catalogue 2016 |
| isoniazid | 300 mg | 18.99 | 1000 | tablets | 0.01899 | per tablet | MSL catalogue 2016 |
| lamivudine (3TC) | 10 mg/mL | 1.87 | 240 |  | 0.01 | per ml | Estimated; relative incr. based on SA data |
| lamivudine (3TC) | 100 mg | 1.60 | 60 | tablets | 0.0266035 | per tablet | Estimated (300mg/3) |
| lamivudine (3TC) | 150 mg | 2.25 | 60 | tablets | 0.0375 | per tablet | MSL catalogue 2016 |
| lamivudine (3TC) | 300 mg | 4.79 | 60 | tablets | 0.0798104 | per tablet | Estimated; relative incr. based on SA data |
| lopinavir+ritonavir | 100 mg + 25 mg |  |  |  | 0.0908407 | per tablet | Estimated; relative incr. based on SA data |
| lopinavir+ritonavir | 133.3 mg + 33.3 mg |  |  |  | 0.1210907 | per tablet | Estimated relative to 100/25 |
| lopinavir+ritonavir | 200 mg + 50 mg | 18.41 | 120 | tablets | 0.1534167 | per tablet | MSL catalogue 2016 |
| lopinavir+ritonavir | 80 mg/mL + 20 mg/mL | 24.33 | 300 | ml | 0.0811 | per ml | MSL catalogue 2016 |
| magnesium trisilicate | 250 mg | 3 | 1000 | tablets | 0.003 | per tablet | MSL catalogue 2016 |
| mebendazole | 100 mg | 9.62 | 1000 | tablets | 0.00962 | per tablet | Estimated |
| medroxyprogesterone acetate | 150 mg/mL | 26.1 | 1 | injection | 26.1 | per injection | MSL catalogue 2016 |
| metronidazole | 200 mg | 2.35 | 1000 | tablets | 0.00235 | per tablet | MSL catalogue 2016 |
| multivitamin | 1 mL |  |  |  | 0.0015361 | per ml | Estimated relative to Pyridoxine |
| multivitamin | 1 unit | 4.9 | 1000 | tablets | 0.0049 | per tablet | MSL catalogue 2016 |
| nevirapine (NVP) | 10 mg/mL | 1.09 | 100 | ml | 0.0109 | per ml | MSL catalogue 2016 |
| nevirapine (NVP) | 200 mg | 2.20 | 60 | tablets | 0.0366667 | per tablet | MSL catalogue 2016 |
| nevirapine (NVP) | 400 mg | 4.4 | 60 | tablets | 0.0733333 | per tablet | Estimated 2x200mg |
| nitrofurantoin | 100 mg | 4.8 | 100 | tablets | 0.048 | per tablet | Estimated 2x50mg |
| nitrofurantoin | 50 mg | 2.4 | 100 | tablets | 0.024 | per tablet | MSL catalogue 2016 |
| norethisterone enanthate | 200 mg/mL | 208.7 | 1 | injection | 208.7 | per injection | MSL catalogue 2016 |
| nystatin | 100000 units | 2.83 | 1 | dose | 2.83 | per injection | MSL catalogue 2016 |
| oral rehydration salts | 27.9 mg/mL | 5 | 100 | sachets | 0.05 | per sachet | MSL catalogue 2016 |
| paracetamol | 500 mg | 3.5 | 1000 | tablets | 0.0035 | per tablet | MSL catalogue 2016 |
| phenoxymethylpenicillin | 250 mg | 6.99 | 1000 | tablets | 0.00699 | per tablet | MSL catalogue 2016 |
| potassium chloride | 1.5 gm/L | 1.86 | 1 | injection | 1.86 | per injection | MSL catalogue 2016 |
| prednisolone | 5 mg | 1.76 | 100 | tablets | 0.0176 | per tablet | MSL catalogue 2016 |
| procaine penicillin | 3000000 units | 8.72 | 1 | injection | 8.72 | per injection | MSL catalogue 2016 |
| pyridoxine (vitamin B6) | 25 mg | 7.15 | 1000 | tablets | 0.00715 | per tablet | Estimated (50mg/2) |
| pyridoxine (vitamin B6) | 50 mg | 14.3 | 1000 | tablets | 0.0143 | per tablet | MSL catalogue 2016 |
| pyrimethamine+sulphadoxine | 25 mg + 500 mg | 45 | 1000 | tablets | 0.045 | per tablet | MSL catalogue 2016 |
| retinol (vitamin A) | 200000 units | 35 | 500 | tablets | 0.07 | per tablet | MSL catalogue 2016 |
| salbutamol | 2 mg | 11.3 | 1000 | tablets | 0.0113 | per tablet | MSL catalogue 2016 |
| stavudine (D4T) | 15 mg |  |  |  | 0.01 | per tablet | Estimated; relative incr. based on SA data |
| stavudine (D4T) | 20 mg |  |  |  | 0.02 | per tablet | Estimated; relative incr. based on SA data |
| stavudine (D4T) | 30 mg |  |  |  | 0.02 | per tablet | Estimated (3TC/D4T minus 3TC) |
| stavudine (D4T) | 40 mg |  |  |  | 0.03 | per tablet | Estimated (20mg x2) |
| sulfamethoxazole+trimethoprim | 100 mg + 20 mg | 1.393 | 1000 | tablets | 0.0013925 | per tablet | Estimated relative to 400/80mg |
| sulfamethoxazole+trimethoprim | 40 mg/mL + 8 mg/mL | 1.35 | 1 | injection | 1.35 | per injection | Estimated relative to 80/16 injection |
| sulfamethoxazole+trimethoprim | 400 mg + 80 mg | 5.57 | 1000 | tablets | 0.00557 | per tablet | MSL catalogue 2016 |
| sulfamethoxazole+trimethoprim | 80 mg/mL + 16 mg/mL | 2.7 | 1 | injection | 2.7 | per injection | MSL catalogue 2016 |
| sulfasalazine | 500 mg | 11.8 | 100 | pills | 0.118 | per tablet | not MSL catalogue 2016, Diclofenac sodium equivalent (50mg is taken twice a day, 500mg once a day initially) |
| tenofovir | 245 mg | 3.60 | 30 | tablets | 0.12 | per tablet | Using 300mg price |
| tenofovir (TDF) | 300 mg | 3.60 | 30 | tablets | 0.12 | per tablet | MSL catalogue 2016 |
| tetracycline eye ointment | 10 mg/mL | 0.18 | 1 | tube | 0.18 | per tube | MSL catalogue 2016 |
| vitamin B-complex | 1 units | 2.5 | 1 | injection | 2.5 | per injection | MSL catalogue 2016 |
| zidovudine (AZT) | 10 mg/mL |  |  |  | 0.0089357 | per ml | Estimated; relative incr. based on SA data |
| zidovudine (AZT) | 100 mg |  |  |  | 0.0438363 | per tablet | Estimated; relative incr. based on SA data |
| zidovudine (AZT) | 300 mg | 5.60 | 60 | tablets | 0.0933333 | per tablet | MSL catalogue 2016 |
| zidovudine (AZT) | 10 mg/mL |  |  |  | 0.0089357 | per ml | Estimated; relative incr. based on SA data |

**SDC 5. Sampling distributions for DMOC visits and ART dispensed at a DMOC in probabilistic sensitivity analysis**

|  |  |  |
| --- | --- | --- |
| **DSD Model** | **Triangular distribution\*** | **Uniform distribution** |
| CAG | Triangular(a=0,b=1,c=0.83) | *U*(0, 1) |
| UAG | Triangular(a=0,b=1,c=0.95) | *U*(0, 1) |
| Home ART delivery | Triangular(a=0,b=1,c=0.79) | *U*(0, 1) |

\*For the triangular distribution, the mode (c) is congruent to the corresponding DSD model’s overall 12-month retention at facility.

**SDC 6. Total costs (2018 USD) of visits and tests conducted at facilities for 12 months, categorized by differentiated model of care (only patients retained at 12 months)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **Model of care** | | | | |
|  | **CAG**  **(N=627)** | **Mobile**  **ART**  **(N=148)** | **UAG**  **(N=183)** | **Home ART delivery**  **(N=134)** | **SOC**  **stable**  **(N=948)** |
| Scenario 1, full DSD use | **Mean annual costs (USD) (SD)** | | | |  |  |
| *Facility visits (pharmacy)* | 4.60 (2.23) | - | 6.51 (1.38) | 2.94 (1.46) | 4.72 (1.78) |
| *Facility visits (non-pharmacy)* | 6.48 (5.10) | - | 5.02 (3.51) | 1.19 (2.72) | 5.31 (3.39) |
| *Laboratory testing* | 7.72 (10.83) | - | 23.93 (16.40) | 5.10 (9.05) | 5.22 (7.88) |
| *Non-ARV drugs* | 0.12 (0.70) | 4.89 (38.66) | 0.19 (0.55) | 0.19 (0.52) | 0.14 (0.56) |
| *ARV drugs* | 103.99 (48.06) | 93.49 (33.01) | 116.61 (49.29) | 126.80 (22.16) | 94.17 (60.48) |
| *DSD interaction cost* | 11.93 (0.00) | 55.75 (17.29) | 11.54 (0.70) | 48.11 (15.18) | - |
| *Total cost (USD)* | 85,004 | 22,811 | 29,950 | 24,701 | 103,853 |
| *Mean (SD) cost per patient* | 135.57 (51.58) | 154.13 (57.02) | 163.66 (53.16) | 184.34 (25.70) | 109.55 (62.32) |
| *Avg cost per person-month* | 11 | 13 | 14 | 15 | 9 |
|  |  |  |  |  |  |  |
|  | **Mean annual costs (USD) (SD)** | | |  |  |  |
| Scenario 2, proportional DSD use | *Facility visits (pharmacy)* | 4.60 (2.23) | - | 6.51 (1.38) | 2.94 (1.46) | 4.72 (1.78) |
| *Facility visits (non-pharmacy)* | 6.48 (5.10) | - | 5.02 (3.51) | 4.65 (5.12) | 5.31 (3.39) |
| *Laboratory testing* | 7.72 (10.83) | - | 23.93 (16.40) | 5.10 (9.05) | 5.22 (7.88) |
| *Non-ARV drugs* | 0.12 (0.70) | 4.89 (38.66) | 0.19 (0.55) | 0.19 (0.52) | 0.14 (0.56) |
| *ARV drugs* | 103.16 (55.27) | 93.49 (33.01) | 104.12 (47.04) | 101.43 (58.61) | 94.17 (60.48) |
| *DSD interaction cost* | 9.92 (0.00) | 55.75 (17.29) | 10.94 (0.67) | 38.14 (12.03) |  |
| *Total cost (USD)* | 83,225 | 22,811 | 27,555 | 19,966 | 103,853 |
| *Mean (SD) cost per patient* | 132.73 (60.45) | 154.13 (57.02) | 150.58 (52.91) | 149.00 (55.23) | 109.55 (62.32) |
| *Avg cost per person-month* | 11 | 13 | 13 | 12 | 9 |

**SDC 7. Total costs (2018 USD) of visits and tests conducted at facilities for 12 months, categorized by differentiated model of care (only patients not retained at 12 months)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **Model of care** | | | | |
|  | **CAG**  **(N=127)** | **Mobile**  **ART**  **(N=68)** | **UAG**  **(N=10)** | **Home ART delivery**  **(N=73)** | **SOC**  **stable**  **(N=268)** |
| Scenario 1, full DSD use | **Mean annual costs (USD) (SD)** | | | |  |  |
| *Facility visits (pharmacy)* | 1.05 (1.34) | - | 2.31 (2.14) | 1.32 (1.17) | 2.65 (1.51) |
| *Facility visits (non-pharmacy)* | 1.46 (2.91) | - | 2.19 (3.08) | 0.73 (1.72) | 3.69 (2.29) |
| *Laboratory testing* | 2.96 (9.54) | - | 10.64 (15.22) | 2.49 (5.59) | 2.05 (6.13) |
| *Non-ARV drugs* | 0.00 (0.02) | 0.32 (0.45) | 0.00 (0.00) | 0.12 (0.40) | 0.09 (0.41) |
| *ARV drugs* | 87.46 (47.79) | 29.37 (29.35) | 79.04 (75.24) | 125.96 (3.67) | 51.95 (35.30) |
| *DSD interaction cost* | 11.93 (0.00) | 23.85 (15.41) | 6.12 (5.35) | 64.19 (11.60) | - |
| *Total cost (USD)* | 13,365 | 3,641 | 1,003 | 6,818 | 13,657 |
| *Mean (SD) cost per patient* | 105.23 (46.01) | 53.55 (39.99) | 100.30 (89.40) | 96.67 (194.80 (12.55) | 60.43 (38.32) |
| *Avg cost per person-month* | 14 | 10 | 15 | 20 | 8 |
|  |  |  |  |  |  |  |
|  | **Mean annual costs (USD) (SD)** | | |  |  |  |
| Scenario 2, proportional DSD use | *Facility visits (pharmacy)* | 1.05 (1.34) | - | 2.31 (2.14) | 1.32 (1.17) | 6.34 (2.95) |
| *Facility visits (non-pharmacy)* | 1.46 (2.91) | - | 2.19 (3.08) | 2.49 (3.25) | 2.65 (1.51) |
| *Laboratory testing* | 2.96 (9.54) | - | 10.64 (15.22) | 2.49 (5.59) | 3.69 (2.29) |
| *Non-ARV drugs* | 0.00 (0.02) | 0.32 (0.45) | 0.00 (0.00) | 0.12 (0.40) | 2.05 (6.13) |
| *ARV drugs* | 14.91 (23.33) | 29.37 (29.35) | 38.96 (49.56) | 36.39 (41.30) | 51.95 (35.30) |
| *DSD interaction cost* | 9.92 (0.00) | 23.85 (15.41) | 5.80 (5.07) | 64.19 (11.60) |  |
| *Total cost (USD)* | 4,430 | 3,641 | 817 | 3,218 | 13,657 |
| *Mean (SD) cost per patient* | 34.88 (36.30) | 53.55 (39.99) | 81.71 (89.87) | 91.94 (38.44) | 60.43 (38.32) |
| *Avg cost per person-month* | 5 | 10 | 12 | 10 | 8 |

**SDC 8. Average and range of cost (USD) per person retained from probabilistic sensitivity analysis (10,000 Monte Carlo simulations)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | ***Model of care*** | | | |
|  | ***CAG*** | ***UAG*** | ***Home ART Delivery*** | ***SOC stable*** |
| *Triangular distribution* |  |  |  |  |
| **Cost per person retained (2018 USD)** | | | | |
| Mean | 154 | 204 | 179 | 124 |
| Range | 152 to 155 | 195 to 212 | 172 to 185 |  |
| **% overlap with CAG** | - | 0% | 0% | 0% |
| **% overlap with UAG** | 0% | - | 0% | 0% |
| **% overlap with Home ART Delivery** | 0% | 0% | - | 0% |
| *Uniform distribution* |  |  |  |  |
| **Cost per person retained (2018 USD)** | | | | |
| Mean | 148 | 186 | 171 | 124 |
| Range | 145 to 151 | 174 to 198 | 162 to 180 |  |
| **% overlap with CAG** | - | 0% | 0% | 0% |
| **% overlap with UAG** | 0% | - | 0% | 0% |
| **% overlap with Home ART Delivery** | 0% | 0% | - | 0% |